ArticleTransplantation direct2026
The Detrimental Outcomes Associated With Kidney Delayed Graft Function Persist Beyond the Short Term.
Article in Transplantation direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Delayed graft function (DGF) is associated with acute rejection (AR) and decreased graft survival, mainly in the early posttransplant period. However, its impact beyond this time is not well known. Methods: All deceased donor kidney-only transplant recipients at our center between June 2005 and December 2019 were stratified based on DGF status (+ versus -). Adjusted hazard ratios (aHRs) of all-cause graft failure (GF), death-censored GF (DCGF), death with a functioning graft (DWFG), and acute rejection (AR) were analyzed within the short-term (0-6 mo) and medium-term (7-36 mo) posttransplant. Results: Of 3093 recipients, 894 (28.9%) experienced DGF. DGF+ recipients were more likely to be older, male, non-White, differ in causes of end-stage kidney disease and utilization of induction immunosuppression, and had a higher degree of HLA mismatches, pretransplant CAD, and congestive heart failure. Donors of DGF+ recipients had higher body mass index, higher donation after circulatory death, higher terminal serum creatinine and kidney donor profile index, were older, and were less likely to be non-White. In the short term, DGF was associated with an increased risk for GF, DCGF, DWFG, and AR. In the medium term, DGF was associated with an increased risk for GF (aHR: 1.39, 95% confidence interval [CI]: 1.11-1.74, Conclusions: DGF recipients remained at significantly higher risk of GF and DWFG beyond the first 6 mo. Close follow-up for DGF patients may mitigate these medium-term outcomes.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.